Tech Center 1600 • Art Units: 1600 1625 1628
This examiner grants 100% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18575739 | METHODS AND COMPOSITIONS FOR TREATMENT OF COVID-19 | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18707780 | DEUTERATED (TRIFLUOROMETHYL)PYRIMIDINE-2-AMINE COMPOUNDS AS POTENTIATORS OF THE HMRGX1 RECEPTOR | Non-Final OA | Eli Lilly and Company |
| 17927624 | ACTIVE COMPOUND COMBINATIONS | Final Rejection | Bayer Aktiengesellschaft |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy